AstraZeneca PLC (AZN)vsVirax Biolabs Group Limited Ordinary Shares (VRAX)
AZN
AstraZeneca PLC
$173.30
-1.13%
HEALTHCARE · Cap: $261.94B
VRAX
Virax Biolabs Group Limited Ordinary Shares
$2.93
+1.38%
HEALTHCARE · Cap: $3.02M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 486626301% more annual revenue ($60.44B vs $12,420). AZN leads profitability with a 17.2% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
VRAX
Avoid33
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+10.7%
Fair Value
$193.96
Current Price
$173.30
$20.66 discount
Margin of Safety
+87.3%
Fair Value
$1.65
Current Price
$2.93
$1.28 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 27.9%
Generating 2.1B in free cash flow
Reasonable price relative to book value
Revenue surging 685.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -230.1% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : VRAX
The strongest argument for VRAX centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 685.0% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : VRAX
The primary concerns for VRAX are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
AZN profiles as a mature stock while VRAX is a hypergrowth play — different risk/reward profiles.
VRAX carries more volatility with a beta of 1.33 — expect wider price swings.
VRAX is growing revenue faster at 685.0% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 33/100), backed by strong 17.2% margins and 12.5% revenue growth. VRAX offers better value entry with a 87.3% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Virax Biolabs Group Limited Ordinary Shares
HEALTHCARE · BIOTECHNOLOGY · USA
Virax Biolabs Group Limited, a biotechnology company, sells, distributes and markets diagnostic test kits and medical technology products and PPE for the prevention, detection, diagnosis and risk management of viral diseases in the field of immunology. The company is headquartered in London, the United Kingdom.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?